Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 4.0Drug Delivery

Hepa-SENS: ASGPR-mediated hepatocyte delivery and attenuated unwanted immune recognition for nucleic acid therapeutics

  1. 1Samyang Biopharm Corporation, R&D Center, Seongnam-si, Republic of Korea

Abstract

An optimal nucleic acid delivery system for hepatic therapeutics should demonstrate consistent pharmacological performance across both normal and diseased hepatic microenvironments, enabling repeated administration with favorable safety profiles. Given the disease-sensitive and relatively low expression of low-density lipoprotein receptor (LDLR) on hepatocytes and compared to the abundant and disease-resilient expression of asialoglycoprotein receptor (ASGPR), ASGPR-mediated drug delivery presents a compelling strategy for liver diseases. Here, we introduce Hepa-SENS, a next-generation polymer-lipid hybrid nanoparticle platform enabling robust ASGPR-mediated hepatocyte delivery without ligand conjugation. Its biodistribution, hepatocyte selectivity, receptor dependence, repeated-dose activity, and therapeutic performance were evaluated in healthy and fibrotic mouse liver models. Hepa-SENS demonstrates strong, hepatocyte-selective transgene expression of mRNA payload preserved under disease conditions, such as high-fatty liver and liver fibrosis, and across multiple species, including non-human primates. In long-term repeat-dose regimens, Hepa-SENS sustained mRNA-driven protein expression without inducing antibodies to the delivery system, enabling greater consistency than conventional lipid nanoparticles (LNPs). In fact, in a liver fibrosis mouse model, where a reduction of LDLR is observed as fibrosis develops, Hepa-SENS outperformed conventional LNPs in delivering therapeutic hepatocyte nuclear factor 4 alpha mRNA and attenuating disease progression. In conclusion, Hepa-SENS represents a robust and versatile delivery platform for nucleic acid therapeutics targeting hepatocytes under disease-relevant conditions via ASGPR-dependent mechanisms. Its repeated-dosing-compatible design supports durable treatment strategies for chronic liver diseases.

Related

  1. PDGFRα-directed fibroblast-homing peptides for targeted delivery of nucleic acid therapeutics
    Shuzhi Cheng, Will Weston, Pierpaolo Ala +8
    bioRxivPreprintAll rights reservedFull textMolecular biology & gene regulationbioRxivPMC
  2. Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
    Kshipra Pandey, Sneha Jha, Loka Bikash Chaliha +2
    Frontiers in NanotechnologyPeer-reviewedCC BY6 citedMolecular biology & gene regulationOpenAlex
  3. Adverse effects of FDA-approved RNA therapeutics: a cross-platform analysis of RNA design, delivery systems, and safety profiles
    Vassiliki Stamatopoulou, Adamantia Kouvela, Konstantina Ahtypi +7
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMCPMCEurope PMC
  4. Type 2B VWD substitutions trigger enhanced macrophage-mediated clearance that is attenuated by the BT200 aptamer
    A. Chion, C. Byrne, A.-M. Hulshof +14
    bioRxivPreprintCC BY-NC-NDFull textGeneral biochemistrybioRxiv
  5. Bone-Directed Drug Delivery: From Mineral and Matrix Recognition to Cellular Regulation
    Raeyeong Kim, Daewon Jeong
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
BibTeX
@article{kim2026hepasens,
  title = {{Hepa-SENS: ASGPR-mediated hepatocyte delivery and attenuated unwanted immune recognition for nucleic acid therapeutics}},
  author = {Goo-Young Kim and Sojin Lee and Hyosuk Kim and Hyejin Park and Yisak Kim and Jihye Choi and Jongmin Kim and Jongmin Park and Joungpyo Nam and Helen Cho},
  journal = {Drug Delivery},
  year = {2026},
  month = nov,
  doi = {10.1080/10717544.2026.2752664},
  url = {https://doi.org/10.1080/10717544.2026.2752664},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Hepa-SENS: ASGPR-mediated hepatocyte delivery and attenuated unwanted immune recognition for nucleic acid therapeutics
AU  - Goo-Young Kim
AU  - Sojin Lee
AU  - Hyosuk Kim
AU  - Hyejin Park
AU  - Yisak Kim
AU  - Jihye Choi
AU  - Jongmin Kim
AU  - Jongmin Park
AU  - Joungpyo Nam
AU  - Helen Cho
PY  - 2026
DA  - 2026/11/04
JO  - Drug Delivery
DO  - 10.1080/10717544.2026.2752664
UR  - https://doi.org/10.1080/10717544.2026.2752664
AB  - An optimal nucleic acid delivery system for hepatic therapeutics should demonstrate consistent pharmacological performance across both normal and diseased hepatic microenvironments, enabling repeated administration with favorable safety profiles. Given the disease-sensitive and relatively low expression of low-density lipoprotein receptor (LDLR) on hepatocytes and compared to the abundant and disease-resilient expression of asialoglycoprotein receptor (ASGPR), ASGPR-mediated drug delivery presents a compelling strategy for liver diseases. Here, we introduce Hepa-SENS, a next-generation polymer-lipid hybrid nanoparticle platform enabling robust ASGPR-mediated hepatocyte delivery without ligand conjugation. Its biodistribution, hepatocyte selectivity, receptor dependence, repeated-dose activity, and therapeutic performance were evaluated in healthy and fibrotic mouse liver models. Hepa-SENS demonstrates strong, hepatocyte-selective transgene expression of mRNA payload preserved under disease conditions, such as high-fatty liver and liver fibrosis, and across multiple species, including non-human primates. In long-term repeat-dose regimens, Hepa-SENS sustained mRNA-driven protein expression without inducing antibodies to the delivery system, enabling greater consistency than conventional lipid nanoparticles (LNPs). In fact, in a liver fibrosis mouse model, where a reduction of LDLR is observed as fibrosis develops, Hepa-SENS outperformed conventional LNPs in delivering therapeutic hepatocyte nuclear factor 4 alpha mRNA and attenuating disease progression. In conclusion, Hepa-SENS represents a robust and versatile delivery platform for nucleic acid therapeutics targeting hepatocytes under disease-relevant conditions via ASGPR-dependent mechanisms. Its repeated-dosing-compatible design supports durable treatment strategies for chronic liver diseases.
SN  - 1071-7544
SN  - 1521-0464
ER  -